Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.230
-0.165 (-4.86%)
At close: Jun 5, 2026, 4:00 PM EDT
3.290
+0.060 (1.86%)
After-hours: Jun 5, 2026, 7:03 PM EDT
Agenus Employees
Agenus had 81 employees as of December 31, 2025. The number of employees decreased by 235 or -74.37% compared to the previous year.
Employees
81
Change (1Y)
-235
Growth (1Y)
-74.37%
Revenue / Employee
$1,529,210
Profits / Employee
$794,951
Market Cap
134.17M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 81 | -235 | -74.37% |
| Dec 31, 2024 | 316 | -73 | -18.77% |
| Dec 31, 2023 | 389 | -144 | -27.02% |
| Dec 31, 2022 | 533 | 92 | 20.86% |
| Dec 31, 2021 | 441 | 82 | 22.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Molecular Partners AG | 134 |
| Alpha Cognition | 71 |
| Connect Biopharma Holdings | 64 |
| Corbus Pharmaceuticals Holdings | 36 |
| Genelux | 26 |
| TuHURA Biosciences | 22 |
| AN2 Therapeutics | 21 |
| Canton Strategic Holdings | 12 |
AGEN News
- 3 days ago - Agenus Announces Virtual 2026 Annual Shareholders Meeting - Business Wire
- 15 days ago - Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC - Business Wire
- 15 days ago - Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 - Business Wire
- 21 days ago - Agenus announces publication of Phase 1b BOT+BAL data - TheFly
- 21 days ago - Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer - Business Wire
- 23 days ago - Agenus Proxy statement: Proxy filing - Filings
- 25 days ago - Agenus reports Q1 revenue $33.7M vs. $24.1M last year - TheFly
- 25 days ago - Agenus provides 2026 strategic priorities - TheFly